

Adrian V Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2354939/publications.pdf>

Version: 2024-02-01

172
papers

12,152
citations

26610

56
h-index

30894

102
g-index

187
all docs

187
docs citations

187
times ranked

17396
citing authors

#	ARTICLE	IF	CITATIONS
1	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018, 173, 400-416.e11.	13.5	2,277
2	Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 7721-7735.	0.8	430
3	Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1254-1261.	3.0	423
4	Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases. <i>Cancer Cell</i> , 2009, 15, 539-550.	7.7	332
5	Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo. <i>Molecular Endocrinology</i> , 1999, 13, 787-796.	3.7	292
6	Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis. <i>Journal of Clinical Oncology</i> , 2008, 26, 4078-4085.	0.8	238
7	Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF- κ B and Snail. <i>Molecular and Cellular Biology</i> , 2007, 27, 3165-3175.	1.1	219
8	Crosstalk between the insulin-like growth factors and estrogens in breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2000, 5, 107-115.	1.0	210
9	Insulin-Like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway: Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer. <i>Molecular Endocrinology</i> , 2003, 17, 575-588.	3.7	207
10	MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv073-djv073.	3.0	189
11	Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor. <i>Cancer Research</i> , 2005, 65, 3781-3787.	0.4	185
12	AIB1/SRC-3 Deficiency Affects Insulin-Like Growth Factor I Signaling Pathway and Suppresses v-Ha-ras-induced Breast Cancer Initiation and Progression in Mice. <i>Cancer Research</i> , 2004, 64, 1875-1885.	0.4	178
13	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1130-1137.	3.2	166
14	Oncogenic Transformation by the Signaling Adaptor Proteins Insulin Receptor Substrate (IRS)-1 and IRS-2. <i>Cell Cycle</i> , 2007, 6, 705-713.	1.3	154
15	Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2. <i>Molecular and Cellular Biology</i> , 2006, 26, 9302-9314.	1.1	152
16	Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. <i>Frontiers in Endocrinology</i> , 2015, 6, 59.	1.5	152
17	A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 5017-5024.	1.6	142
18	Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data. <i>Nucleic Acids Research</i> , 2016, 44, e47-e47.	6.5	141

#	ARTICLE	IF	CITATIONS
19	Intrinsic Subtype Switching and Acquired <i>ERBB2</i> / <i>HER2</i> Amplifications and Mutations in Breast Cancer Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 666.	3.4	135
20	Mutation site and context dependent effects of <i>ESR1</i> mutation in genome-edited breast cancer cell models. <i>Breast Cancer Research</i> , 2017, 19, 60.	2.2	116
21	Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. <i>Small</i> , 2018, 14, e1801131.	5.2	115
22	Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF- κ B signaling. <i>Journal of Clinical Investigation</i> , 2011, 121, 212-225.	3.9	114
23	Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3-Kinase Inhibition. <i>Molecular and Cellular Biology</i> , 2000, 20, 1489-1496.	1.1	113
24	High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 2314-2327.	3.2	112
25	A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. <i>Genome Research</i> , 2009, 19, 167-177.	2.4	111
26	Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. <i>JCI Insight</i> , 2017, 2, .	2.3	111
27	The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 3273.	3.0	108
28	Disruption of Steroid and Prolactin Receptor Patterning in the Mammary Gland Correlates with a Block in Lobuloalveolar Development. <i>Molecular Endocrinology</i> , 2002, 16, 2675-2691.	3.7	105
29	The IGF Pathway Regulates ER α through a S6K1-Dependent Mechanism in Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2011, 25, 516-528.	3.7	99
30	Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. <i>Journal of Endocrinology</i> , 2006, 191, 605-612.	1.2	96
31	Activation of renal signaling pathways in db/db mice with type 2 diabetes. <i>Kidney International</i> , 2001, 60, 495-504.	2.6	94
32	Molecular profiles of progesterone receptor loss in human breast tumors. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 287-299.	1.1	94
33	Local Insulin-Like Growth Factor-II Mediates Prolactin-Induced Mammary Gland Development. <i>Molecular Endocrinology</i> , 2003, 17, 460-471.	3.7	91
34	Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation. <i>Molecular Endocrinology</i> , 2000, 14, 369-381.	3.7	89
35	The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 315-327.	1.1	88
36	Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types. <i>Cell Reports</i> , 2016, 17, 2075-2086.	2.9	84

#	ARTICLE	IF	CITATIONS
37	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. <i>Journal of the National Cancer Institute</i> , 2019, 111, 388-398.	3.0	81
38	Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo. <i>Molecular Endocrinology</i> , 1999, 13, 787-796.	3.7	81
39	SAFB2, a New Scaffold Attachment Factor Homolog and Estrogen Receptor Corepressor. <i>Journal of Biological Chemistry</i> , 2003, 278, 20059-20068.	1.6	76
40	Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. <i>Cancer Research</i> , 2003, 63, 5203-8.	0.4	75
41	GLUT4 Distribution between the Plasma Membrane and the Intracellular Compartments Is Maintained by an Insulin-modulated Bipartite Dynamic Mechanism. <i>Journal of Biological Chemistry</i> , 2006, 281, 484-490.	1.6	74
42	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5362-5369.	3.2	73
43	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. <i>Annals of Oncology</i> , 2018, 29, 872-880.	0.6	73
44	Epidermal Growth Factor Induces Insulin Receptor Substrate-2 in Breast Cancer Cells via c-Jun NH2-Terminal Kinase/Activator Protein-1 Signaling to Regulate Cell Migration. <i>Cancer Research</i> , 2006, 66, 5304-5313.	0.4	72
45	Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer. <i>Science Translational Medicine</i> , 2014, 6, 229ra41.	5.8	72
46	Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. <i>Scientific Reports</i> , 2018, 8, 7205.	1.6	71
47	Igf system components as prognostic markers in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 295-302.	1.1	70
48	Sustained c-Jun-NH2-Kinase Activity Promotes Epithelial-Mesenchymal Transition, Invasion, and Survival of Breast Cancer Cells by Regulating Extracellular Signal-Regulated Kinase Activation. <i>Molecular Cancer Research</i> , 2010, 8, 266-277.	1.5	70
49	Cloning, Chromosome Localization, Expression, and Characterization of an Src Homology 2 and Pleckstrin Homology Domain-containing Insulin Receptor Binding Protein hGrb10 ³ . <i>Journal of Biological Chemistry</i> , 1997, 272, 29104-29112.	1.6	69
50	Increases in estrogen receptor- α concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. <i>FASEB Journal</i> , 2004, 18, 81-93.	0.2	69
51	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. , 2019, 7, 265.		68
52	Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM. <i>Molecular and Cellular Biology</i> , 2010, 30, 399-412.	1.1	67
53	The Cellular Origin and Evolution of Breast Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a027128.	2.9	67
54	Insulin Receptor Substrates (IRSs) and Breast Tumorigenesis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 415-422.	1.0	66

#	ARTICLE	IF	CITATIONS
55	The CARMA3-Bcl10-MALT1 Signalosome Drives NF κ B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2018, 78, 1225-1240.	0.4	65
56	Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 1994, 99, 211-220.	1.6	62
57	TCGA Expedition: A Data Acquisition and Management System for TCGA Data. <i>PLoS ONE</i> , 2016, 11, e0165395.	1.1	62
58	Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. <i>Cancer Medicine</i> , 2015, 4, 989-994.	1.3	61
59	Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor- α -positive human cells. <i>Environmental Research</i> , 2006, 100, 86-92.	3.7	60
60	Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition. <i>Clinical Cancer Research</i> , 2010, 16, 4654-4665.	3.2	58
61	<i>THADA</i> fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2307-2312.	3.3	58
62	Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 5165-5177.	3.2	58
63	Structure-Function Analysis of the Estrogen Receptor α Corepressor Scaffold Attachment Factor-B1. <i>Journal of Biological Chemistry</i> , 2004, 279, 26074-26081.	1.6	56
64	The molecular landscape of premenopausal breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 104.	2.2	56
65	Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide. <i>Journal of Biological Chemistry</i> , 2016, 291, 13495-13508.	1.6	56
66	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. <i>Breast Cancer Research</i> , 2016, 18, 92.	2.2	56
67	Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1013s-1018s.	3.2	54
68	Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery. <i>PLoS ONE</i> , 2014, 9, e102678.	1.1	50
69	Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. <i>Endocrinology</i> , 2016, 157, 3760-3766.	1.4	50
70	Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 161-173.	0.2	50
71	Abstract 3287: An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics. <i>Cancer Research</i> , 2018, 78, 3287-3287.	0.4	49
72	Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. <i>Oncogene</i> , 2003, 22, 6937-6941.	2.6	47

#	ARTICLE	IF	CITATIONS
73	Scaffold Attachment Factor B1 Functions in Development, Growth, and Reproduction. <i>Molecular and Cellular Biology</i> , 2005, 25, 2995-3006.	1.1	47
74	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. <i>Npj Breast Cancer</i> , 2019, 5, 19.	2.3	46
75	Crystal Structure of the SH3 Domain of Î²PIX in Complex with a High Affinity Peptide from PAK2. <i>Journal of Molecular Biology</i> , 2006, 358, 509-522.	2.0	45
76	Novel egg white-based 3-D cell culture system. <i>BioTechniques</i> , 2008, 45, 165-171.	0.8	45
77	BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells. <i>Clinical Cancer Research</i> , 2009, 15, 226-237.	3.2	43
78	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. <i>Clinical Cancer Research</i> , 2017, 23, 3802-3812.	3.2	43
79	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. <i>Breast Cancer Research</i> , 2021, 23, 1.	2.2	43
80	Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats. <i>Carcinogenesis</i> , 2001, 22, 2039-2047.	1.3	42
81	Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. <i>Oncotarget</i> , 2017, 8, 66901-66911.	0.8	40
82	Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 61-73.	1.1	39
83	Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. <i>Developmental Biology</i> , 2007, 309, 137-149.	0.9	38
84	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. <i>Nature Communications</i> , 2022, 13, 514.	5.8	38
85	Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2004, 221, 47-55.	1.6	37
86	The WT1 Wilms tumor suppressor gene product interacts with estrogen receptor-Î± and regulates IGF-I receptor gene transcription in breast cancer cells. <i>Journal of Molecular Endocrinology</i> , 2005, 35, 135-144.	1.1	33
87	Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. <i>Molecular and Cellular Endocrinology</i> , 2007, 277, 13-25.	1.6	32
88	Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. <i>Endocrinology</i> , 2018, 159, 285-296.	1.4	32
89	Precision Medicine in Hormone Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 144.	1.3	32
90	Systematic discovery of the functional impact of somatic genome alterations in individual tumors through tumor-specific causal inference. <i>PLoS Computational Biology</i> , 2019, 15, e1007088.	1.5	31

#	ARTICLE	IF	CITATIONS
91	The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2019, 142, 1-10.	1.4	31
92	The center for causal discovery of biomedical knowledge from big data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1132-1136.	2.2	30
93	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. <i>Hormones and Cancer</i> , 2015, 6, 214-224.	4.9	30
94	Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2019, 141, 1-12.	1.4	30
95	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. <i>Cancer Research</i> , 2022, 82, 1321-1339.	0.4	30
96	Altered mammary gland development in the p53 ^{+/m} mouse, a model of accelerated aging. <i>Developmental Biology</i> , 2008, 313, 130-141.	0.9	29
97	Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 3479-3485.	3.2	29
98	Frequent <i>ESR1</i> and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 457-468.	1.5	29
99	<i>ESR1</i> mutant breast cancers show elevated basal cytokeratins and immune activation. <i>Nature Communications</i> , 2022, 13, 2011.	5.8	29
100	Targeted mutation detection in breast cancer using MammaSeq [®] . <i>Breast Cancer Research</i> , 2019, 21, 22.	2.2	28
101	Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. <i>Cancer Research</i> , 2021, 81, 268-281.	0.4	28
102	Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model. <i>Cancer and Clinical Oncology</i> , 2016, 6, 12.	0.2	27
103	Decreased lactation capacity and altered milk composition in insulin receptor substrate null mice is associated with decreased maternal body mass and reduced insulin-dependent phosphorylation of mammary Akt. <i>Journal of Endocrinology</i> , 2007, 194, 327-336.	1.2	24
104	Cross Talk Between Estrogen Receptor and IGF Signaling in Normal Mammary Gland Development and Breast Cancer. <i>Breast Disease</i> , 2003, 17, 105-114.	0.4	23
105	Serine ^ε -derivatized gadonanotubes as magnetic nanoprobe for intracellular labeling. <i>Contrast Media and Molecular Imaging</i> , 2010, 5, 34-38.	0.4	23
106	Forkhead box A1 (FOXA1) is a key mediator of insulin ^α -like growth factor I (IGF ^α) activity. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 110-121.	1.2	22
107	Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3045-3057.	2.5	22
108	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. <i>Scientific Reports</i> , 2018, 8, 17313.	1.6	22

#	ARTICLE	IF	CITATIONS
109	Progesterone Receptor-B Regulation of Insulin-Like Growth Factor- α Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2. <i>Molecular Cancer Research</i> , 2008, 6, 1491-1498.	1.5	21
110	Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 651-660.	1.1	21
111	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. <i>JCI Insight</i> , 2018, 3, .	2.3	21
112	Overexpression of Des(1-3) Insulin-Like Growth Factor 1 in the Mammary Glands of Transgenic Mice Delays the Loss of Milk Production with Prolonged Lactation1. <i>Biology of Reproduction</i> , 2005, 73, 1116-1125.	1.2	20
113	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 311-321.	1.1	20
114	High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. <i>Gynecologic Oncology</i> , 2016, 141, 348-356.	0.6	20
115	Spatial Statistics for Segmenting Histological Structures in H&E Stained Tissue Images. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 1522-1532.	5.4	20
116	Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes. <i>Oncology</i> , 2018, 94, 176-189.	0.9	20
117	Platform for Quantitative Evaluation of Spatial Intratumoral Heterogeneity in Multiplexed Fluorescence Images. <i>Cancer Research</i> , 2017, 77, e71-e74.	0.4	19
118	Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. <i>Cancer Letters</i> , 2019, 461, 21-30.	3.2	18
119	Exosomes in Breast Cancer - Mechanisms of Action and Clinical Potential. <i>Molecular Cancer Research</i> , 2021, 19, 935-945.	1.5	18
120	Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers. <i>Journal of Pathology Informatics</i> , 2016, 7, 47.	0.8	18
121	A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. <i>Journal of Personalized Medicine</i> , 2021, 11, 1031.	1.1	18
122	Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 540-548.	1.0	17
123	Disruption of Scaffold Attachment Factor B1 Leads to TBX2 Up-regulation, Lack of p19ARF Induction, Lack of Senescence, and Cell Immortalization. <i>Cancer Research</i> , 2006, 66, 7859-7863.	0.4	17
124	Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma. <i>Endocrinology</i> , 2020, 161, .	1.4	17
125	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. <i>Cancers</i> , 2021, 13, 5396.	1.7	17
126	Long-range massively parallel mate pair sequencing detects distinct mutations and similar patterns of structural mutability in two breast cancer cell lines. <i>Cancer Genetics</i> , 2011, 204, 447-457.	0.2	16

#	ARTICLE	IF	CITATIONS
127	Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of <i>Igf1r</i> That Persists Long after Parturition. <i>Cancer Prevention Research</i> , 2015, 8, 1000-1009.	0.7	16
128	Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. <i>Scientific Reports</i> , 2020, 10, 11487.	1.6	16
129	Parity-Induced Decrease in Systemic Growth Hormone Alters Mammary Gland Signaling: A Potential Role in Pregnancy Protection from Breast Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 312-321.	0.7	15
130	Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. <i>Breast Cancer Research</i> , 2020, 22, 70.	2.2	15
131	Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. <i>JAMA Network Open</i> , 2021, 4, e216322.	2.8	15
132	The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor. <i>Molecular and Cellular Endocrinology</i> , 2015, 415, 76-86.	1.6	13
133	Expression of reactive species related genes is associated with patient survival in luminal B breast cancer. <i>Free Radical Biology and Medicine</i> , 2018, 120, 170-180.	1.3	13
134	Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0150564.	1.1	13
135	Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. <i>Journal of Biological Chemistry</i> , 2018, 293, 3700-3709.	1.6	12
136	IGF1R constitutive activation expands luminal progenitors and influences lineage differentiation during breast tumorigenesis. <i>Developmental Biology</i> , 2020, 463, 77-87.	0.9	12
137	Expression of high affinity folate receptor in breast cancer brain metastasis. <i>Oncotarget</i> , 2015, 6, 30327-30333.	0.8	12
138	Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. <i>Cureus</i> , 2017, 9, e1434.	0.2	12
139	New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. <i>Clinical Cancer Research</i> , 2017, 23, 1126-1131.	3.2	11
140	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. <i>Oncogene</i> , 2021, 40, 1318-1331.	2.6	10
141	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. <i>Cancer Research</i> , 2021, 81, 6259-6272.	0.4	10
142	New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. <i>Clinical Cancer Research</i> , 2003, 9, 516S-23S.	3.2	10
143	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 62.	2.3	10
144	Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer. <i>Cell Communication and Signaling</i> , 2016, 14, 25.	2.7	9

#	ARTICLE	IF	CITATIONS
145	Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. <i>The Lancet Healthy Longevity</i> , 2022, 3, e54-e66.	2.0	9
146	Inability of Overexpressed des(1 $\hat{=}$ 3)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules. , 0, .		8
147	Integration of cancer registry data into the text information extraction system: Leveraging the structured data import tool. <i>Journal of Pathology Informatics</i> , 2018, 9, 47.	0.8	8
148	Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 392-398.	0.6	7
149	Robust and accurate deconvolution of tumor populations uncovers evolutionary mechanisms of breast cancer metastasis. <i>Bioinformatics</i> , 2020, 36, i407-i416.	1.8	7
150	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 373-386.	1.5	7
151	Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 1405-1419.	1.5	7
152	Scaffold attachment factor B2 (SAFB2) null mice reveal non-redundant functions compared to its paralog SAFB1. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1121-7.	1.2	6
153	Genomics, drug approval, and optimal treatment duration. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 71-72.	12.5	5
154	Non-coding single nucleotide variants affecting estrogen receptor binding and activity. <i>Genome Medicine</i> , 2016, 8, 128.	3.6	5
155	Network-guided prediction of aromatase inhibitor response in breast cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006730.	1.5	5
156	A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer Metastasis. <i>Endocrinology</i> , 2021, 162, .	1.4	5
157	Molecular Biology Information Service: an innovative medical library-based bioinformatics support service for biomedical researchers. <i>Briefings in Bioinformatics</i> , 2020, 21, 876-884.	3.2	4
158	Identifying Genomic Alterations in Patients With Stage IV Breast Cancer Using MammaSeq: An International Collaborative Study. <i>Clinical Breast Cancer</i> , 2021, 21, 210-217.	1.1	4
159	Prognostic factors and survival of patients undergoing surgical intervention for breast cancer bone metastases. <i>Journal of Bone Oncology</i> , 2021, 29, 100363.	1.0	4
160	Isoforms of Neuropilin-2 Denote Unique Tumor-Associated Macrophages in Breast Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
161	Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations. <i>Cancer Research</i> , 2016, 76, 6785-6794.	0.4	3
162	Neural Network Deconvolution Method for Resolving Pathway-Level Progression of Tumor Clonal Expression Programs With Application to Breast Cancer Brain Metastases. <i>Frontiers in Physiology</i> , 2020, 11, 1055.	1.3	3

#	ARTICLE	IF	CITATIONS
163	Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. PLoS Computational Biology, 2021, 17, e1009125.	1.5	3
164	Phylogenies Derived from Matched Transcriptome Reveal the Evolution of Cell Populations and Temporal Order of Perturbed Pathways in Breast Cancer Brain Metastases. Lecture Notes in Computer Science, 2019, , 3-28.	1.0	3
165	Abstract PS17-31: Investigating the estrogen receptor Y537S mutation in transgenic models of luminal B breast cancer. , 2021, , .		2
166	Intratumor Heterogeneity. , 2019, , 17-30.		1
167	The Development and Implementation of an Autopsy/ Tissue Donation for Breast Cancer Research. New Bioethics, 2021, 27, 349-361.	0.5	1
168	The evolving role of multi-gene tests in breast cancer management. Oncology, 2013, 27, 210, 212, 214.	0.4	1
169	Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nature Clinical Practice Oncology, 2006, 3, 134-135.	4.3	0
170	The Endocrine Society Centennial: 40 Years of Aromatase Inhibitors as Targeted Therapy for Breast Cancer. Endocrinology, 2016, 157, 3697-3698.	1.4	0
171	Genetic Background Influences Patterning and Implementation of Stereotypy in the Early Postnatal Mammary Ductal Tree. FASEB Journal, 2017, 31, 896.10.	0.2	0
172	Semi-deconvolution of bulk and single-cell RNA-seq data with application to metastatic progression in breast cancer. Bioinformatics, 2022, 38, i386-i394.	1.8	0